达格列净在射血分数降低心衰中的临床获益时机及既往心衰住院意义
该研究为DAPA-HF试验的二次分析,纳入4744例慢性HFrEF患者,评估达格列净临床获益的起始时间及与既往心衰住院时间的关系。结果显示,达格列净在随机化后28天即显著降低主要复合终点风险(HR 0.51),且近期心衰住院患者相对和绝对风险降低幅度更大。
要点
- 既往心衰住院越近,安慰剂组主要终点2年KM率越高(21.1%、25.3%、33.8%)。
- 近期住院患者达格列净相对风险降低36%(HR 0.64),绝对风险降低9.9%。
核心结论
- 达格列净可快速降低心血管死亡或心衰恶化风险,随机化后早期即出现持续显著获益。
- 近期心衰住院患者风险更高,达格列净带来的相对和绝对风险降低幅度更大。
研究设计与样本
- DAPA-HF试验的二次分析,为多国、双盲、安慰剂对照随机临床试验。
- 共纳入4744例慢性HFrEF患者,NYHA心功能II-IV级,左室射血分数≤40%。
- 中位随访时间18.2个月(范围0-27.8个月)。
临床怎么用
- HFrEF患者应尽早启动达格列净治疗,无需等待,因获益在28天内即显现。
- 近期心衰住院患者风险最高,达格列净治疗绝对获益更大,应优先考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction (HFrEF). However, clinical inertia often underlies deferred initiation of effective therapies. OBJECTIVE: To examine timing of onset of clinical benefit with dapagliflozin and magnitude as a function of proximity to prior HF hospitalization. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of a completed multinational trial. The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure trial was a double-blind, placebo-controlled randomized clinical trial of dapagliflozin in patients with chronic HFrEF (n = 4744). From February 2017 to August 2018, the study enrolled patients in New York Heart Association classes II through IV and with left ventricular ejection fraction of 40% or less; the median (range) follow-up time was 18.2 (0-27.8) months. Hazard ratios (HRs) were calculated for the primary efficacy outcome with dapagliflozin vs placebo by time following randomization. Efficacy and safety of dapagliflozin were assessed according to the timing of the most recent HF hospitalization prior to trial enrollment. EXPOSURES: None. MAIN OUTCOMES AND MEASURES: Composite of cardiovascular death or worsening HF. RESULTS: A total of 4744 patients were included (1109 women [23.4%]; mean [SD] age, 66.3 [10.9] years). The reduction in the primary outcome with dapagliflozin was rapidly apparent, with a sustained statistically significant benefit by 28 days after randomization (HR at 28 days, 0.51 [95% CI, 0.28-0.94]; P = .03). A total of 2251 patients (47.4%) had been previously hospitalized for HF, and 1301 (27.4%) had been hospitalized within 12 months prior to enrollment. Among patients treated with placebo, there was a stepwise gradient of risk for the primary outcome according to timing of most recent HF hospitalization, with 2-year Kaplan-Meier rates of 21.1%, 25.3%, and 33.8% (adjusted P = .003) for patients with a prior HF hospitalization never, more than 12 months ago, and 12 or fewer months ago, respectively. Across these subgroups, dapagliflozin reduced the relative risk of the primary outcome by 16% (HR, 0.84 [95% CI, 0.69-1.01]), 27% (HR, 0.73 [95% CI, 0.54-0.99]), and 36% (HR, 0.64 [95% CI, 0.51-0.80]), respectively (P = .07 for trend). Accordingly, patients with a more recent HF hospitalization tended to experience greater absolute risk reductions with dapagliflozin at 2 years: 2.1% (95% CI, -1.9% to 6.1%), 4.1% (95% CI, -3.6% to 11.7%), and 9.9% (95% CI, 3.3%-16.5%), respectively (P = .05 for trend). CONCLUSIONS AND RELEVANCE: In this study, treatment with dapagliflozin was associated with rapid reduction in the risk of cardiovascular death or worsening HF, with a sustained statistically significant benefit emerging very early after randomization. Patients with a more recent HF hospitalization were at particularly high risk and experienced greater relative and absolute risk reductions with dapagliflozin. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03036124.
引用
- Berg DD, Jhund PS, Docherty KF, et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021. PMID: 33595593. doi:10.1001/jamacardio.2020.7585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。